Transcript

More and more, when people are doing molecular testing on their tumor, they’re not just getting one test and if it’s negative doing another test — that’s called sequential testing, they’re doing lots of tests at the same time — that’s called multiplex testing. There are certain good things about that and certain things which are less than good.

Drs. Ben Solomon, Leora Horn, & Jack West evaluate the merits of broad genetic testing with a "next generation sequencing" platform compared to selective, limited testing for the most proven driver mutations in patients with advanced NSCLC.

Dr. Oxnard from Dana Farber Cancer Institute provides his insight on which patients with advanced non-small cell lung cancer he pursues molecular testing for, and which molecular markers are the highest priority.

[powerpress]